Technical Analysis for CCCC - C4 Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
New Uptrend | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Crossed Above 20 DMA | Bullish | -5.01% | |
Bollinger Band Squeeze | Range Contraction | -5.01% | |
20 DMA Resistance | Bearish | -3.87% | |
Bollinger Band Squeeze | Range Contraction | -3.87% | |
BB Squeeze Started | Range Contraction | -3.87% | |
20 DMA Resistance | Bearish | -4.30% |
Alert | Time |
---|---|
10 DMA Support | about 15 hours ago |
Down 5% | about 17 hours ago |
Fell Below 10 DMA | about 17 hours ago |
Outside Day | about 17 hours ago |
Fell Below Previous Day's Low | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
C4 Therapeutics, Inc. Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.88 |
52 Week Low | 1.06 |
Average Volume | 1,954,080 |
200-Day Moving Average | 4.76 |
50-Day Moving Average | 8.18 |
20-Day Moving Average | 6.72 |
10-Day Moving Average | 6.47 |
Average True Range | 0.47 |
RSI (14) | 39.02 |
ADX | 25.55 |
+DI | 20.32 |
-DI | 19.64 |
Chandelier Exit (Long, 3 ATRs) | 6.66 |
Chandelier Exit (Short, 3 ATRs) | 7.54 |
Upper Bollinger Bands | 7.48 |
Lower Bollinger Band | 5.96 |
Percent B (%b) | 0.33 |
BandWidth | 22.64 |
MACD Line | -0.35 |
MACD Signal Line | -0.43 |
MACD Histogram | 0.0749 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.85 | ||||
Resistance 3 (R3) | 7.97 | 7.63 | 7.61 | ||
Resistance 2 (R2) | 7.63 | 7.27 | 7.57 | 7.53 | |
Resistance 1 (R1) | 7.04 | 7.06 | 6.87 | 6.92 | 7.46 |
Pivot Point | 6.70 | 6.70 | 6.62 | 6.64 | 6.70 |
Support 1 (S1) | 6.11 | 6.34 | 5.94 | 5.99 | 5.44 |
Support 2 (S2) | 5.77 | 6.13 | 5.71 | 5.37 | |
Support 3 (S3) | 5.18 | 5.77 | 5.29 | ||
Support 4 (S4) | 5.06 |